Cheplapharm Schweiz GmbH
Cheplapharm Schweiz GmbH is a Originators company based in Binningen (Basel-Landschaft) recorded by Swissmedic as the authorisation holder for 59 human medicines. That places it 25 of 334 authorisation holders in Switzerland. Its portfolio is concentrated in Synthetika.
Key facts
| Sector | Originators |
|---|---|
| City | Binningen |
| Canton | Basel-Landschaft |
| Authorisation holder | Yes |
| Medicines | 59 |
| Founded | 2023 |
| Employees | 1-10 |
| Parent group | Cheplapharm Arzneimittel GmbH |
| Activity | Not available |
| Website | cheplapharm.ch |
Medicines authorised in Switzerland
Cheplapharm Schweiz GmbH is recorded by Swissmedic as the authorisation holder for 59 human medicines. The table shows 48 of them with product code and dispensing category.
Portfolio by product code
Portfolio by dispensing category
48 of 59 authorisations
| Name | Authorisation number | Dispensing category | ATC | First authorised |
|---|---|---|---|---|
| Actos 15 mg | 55378 | B | A10BG03 | 2000-09-27 |
| Anexate | 48280 | B | V03AB25 | 1986-12-30 |
| Antramups 10 | 54380 | B | A02BC01 | 1997-12-19 |
| Atacand 4 mg | 54230 | B | C09CA06 | 1997-08-26 |
| Atacand plus 8/12.5 mg | 54875 | B | C09DA06 | 1999-03-24 |
| Blopress 4 mg | 54260 | B | C09CA06 | 1997-08-26 |
| Blopress Plus 8/12.5 mg | 55247 | B | C09DA06 | 2000-02-11 |
| Calcimagon-D3 | 53929 | D | A12AX | 1997-04-22 |
| CANDESARTAN CHEPLAPHARM 4 mg | 62569 | B | C09CA06 | 2012-03-12 |
| CANDESARTAN PLUS CHEPLAPHARM 8/12.5 mg | 62570 | B | C09DA06 | 2012-03-12 |
| Competact 15/850 mg | 57725 | B | A10BD05 | 2007-02-02 |
| Corvaton | 41958 | B | C01DX12 | 1980-11-10 |
| Corvaton retard | 48105 | B | C01DX12 | 1990-02-21 |
| Cymevene | 49188 | A | J05AB06 | 1988-12-19 |
| De-ursil 150 mg | 41655 | B | A05AA02 | 1978-12-21 |
| De-ursil RR 450 mg | 44619 | B | A05AA02 | 1983-06-28 |
| Dilatrend 12 | 53162 | B | C07AG02 | 1995-08-29 |
| Distraneurin | 40629 | A | N05CM02 | 1978-08-31 |
| Distraneurin Mixtur | 40632 | A | N05CM02 | 1978-08-31 |
| Dormicum 15 mg | 45163 | B | N05CD08 | 1983-05-17 |
| Dormicum 5 mg/1 mL | 44448 | B | N05CD08 | 1982-09-10 |
| Ebrantil 50 mg | 44486 | B | C02CA06 | 1983-07-21 |
| Etopophos 113.6 mg | 53557 | A | L01CB01 | 1996-08-28 |
| Fluidose | 57779 | D | S01XA20 | 2007-10-10 |
| Fungizone | 31096 | A | J02AA01 | 1964-11-05 |
| Gutron | 44976 | B | C01CA17 | 1985-06-17 |
| Gutron | 44977 | B | C01CA17 | 1985-06-17 |
| Inhibace Plus | 52472 | B | C09BA08 | 1994-06-02 |
| Inhibace submite 1 mg | 50373 | B | C09AA08 | 1990-02-21 |
| Konakion MM | 48112 | B | B02BA01 | 1987-02-13 |
| Lacrifluid | 57824 | D | S01XA20 | 2007-09-06 |
| Lexotanil 1 | 38294 | B | N05BA08 | 1974-07-15 |
| Litalir | 52958 | A | L01XX05 | 1995-04-27 |
| Locoid | 36481 | B | D07AB02 | 1973-11-01 |
| Locoid Crelo | 52585 | B | D07AB02 | 1994-06-28 |
| Paraplatin 150 mg/15 ml | 47671 | A | L01XA02 | 1986-08-26 |
| Quantalan | 50711 | B | C10AC01 | 1990-01-19 |
| Rivotril | 37756 | B | N03AE01 | 1973-06-27 |
| Rivotril | 37758 | B | N03AE01 | 1973-06-27 |
| Rivotril 0.5 mg | 37757 | B | N03AE01 | 1973-06-27 |
| Roaccutan 10 mg | 45307 | A | D10BA01 | 1983-06-15 |
| Rohypnol 1 mg | 54959 | B | N05CD03 | 1998-07-13 |
| Selectol | 44421 | B | C07AB08 | 1987-06-26 |
| Sequase 25 mg | 62331 | B | N05AH04 | 2011-09-01 |
| Sequase XR 50 mg | 63255 | B | N05AH04 | 2013-10-01 |
| Seroquel 25 mg | 54182 | B | N05AH04 | 1999-12-23 |
| Seroquel XR 50 mg | 58108 | B | N05AH04 | 2008-08-19 |
| Tarceva 25 mg | 57266 | A | L01EB02 | 2005-03-21 |
Frequently asked questions
How many medicines does Cheplapharm Schweiz GmbH have authorised in Switzerland?
Cheplapharm Schweiz GmbH is recorded by Swissmedic as the authorisation holder for 59 human medicines (as of 1 September 2026). Different strengths under one authorisation number are not counted separately.
Where is Cheplapharm Schweiz GmbH based?
The Swiss location recorded for Cheplapharm Schweiz GmbH is Binningen, Basel-Landschaft.
Is Cheplapharm Schweiz GmbH a Swissmedic authorisation holder?
Yes. Cheplapharm Schweiz GmbH appears in the official Swissmedic list of authorised medicinal products as an authorisation holder. Under the Therapeutic Products Act (TPA) the holder is responsible for the quality, safety and product information of its medicines in Switzerland.